S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
NASDAQ:STOK

Stoke Therapeutics (STOK) Stock Forecast, Price & News

$13.08
-0.12 (-0.91%)
(As of 06/7/2023 ET)
Compare
Today's Range
$12.86
$13.40
50-Day Range
$7.93
$13.20
52-Week Range
$6.88
$22.87
Volume
137,346 shs
Average Volume
175,781 shs
Market Capitalization
$578.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.50

Stoke Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
95.0% Upside
$25.50 Price Target
Short Interest
Bearish
17.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
0.16mentions of Stoke Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$667,048 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.53) to ($3.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

550th out of 981 stocks

Pharmaceutical Preparations Industry

261st out of 477 stocks


STOK stock logo

About Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Stock News Headlines

Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
12 Analysts Have This to Say About Stoke Therapeutics
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
H.C. Wainwright Remains a Buy on Stoke Therapeutics (STOK)
See More Headlines

STOK Price History

STOK Company Calendar

Last Earnings
5/04/2023
Today
6/08/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STOK
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.50
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+95.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-101,070,000.00
Net Margins
-679.83%
Pretax Margin
-679.83%

Debt

Sales & Book Value

Annual Sales
$12.40 million
Book Value
$4.69 per share

Miscellaneous

Free Float
38,577,000
Market Cap
$578.01 million
Optionable
Not Optionable
Beta
0.40

Key Executives

  • Edward M. KayeEdward M. Kaye
    Chief Executive Officer & Director
  • Huw M. NashHuw M. Nash
    Chief Operating & Business Officer
  • Stephen J. Tulipano
    Chief Financial Officer
  • Barry S. TichoBarry S. Ticho
    Chief Medical Officer
  • Isabel Aznarez
    Group Vice President-Discovery Research













STOK Stock - Frequently Asked Questions

Should I buy or sell Stoke Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STOK shares.
View STOK analyst ratings
or view top-rated stocks.

What is Stoke Therapeutics' stock price forecast for 2023?

8 brokerages have issued 1 year price targets for Stoke Therapeutics' shares. Their STOK share price forecasts range from $12.00 to $35.00. On average, they anticipate the company's stock price to reach $25.50 in the next year. This suggests a possible upside of 95.0% from the stock's current price.
View analysts price targets for STOK
or view top-rated stocks among Wall Street analysts.

How have STOK shares performed in 2023?

Stoke Therapeutics' stock was trading at $9.23 at the beginning of 2023. Since then, STOK shares have increased by 41.7% and is now trading at $13.08.
View the best growth stocks for 2023 here
.

When is Stoke Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our STOK earnings forecast
.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its earnings results on Thursday, May, 4th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.70) by $0.17. The company earned $5.15 million during the quarter, compared to the consensus estimate of $3.57 million. Stoke Therapeutics had a negative trailing twelve-month return on equity of 47.86% and a negative net margin of 679.83%.

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RTW Investments LP (9.94%), Cowen AND Company LLC (7.42%), Baker BROS. Advisors LP (4.79%), FMR LLC (4.45%), BlackRock Inc. (4.18%) and Deutsche Bank AG (1.62%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker and Stephen J Tulipano.
View institutional ownership trends
.

How do I buy shares of Stoke Therapeutics?

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $13.08.

How much money does Stoke Therapeutics make?

Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $578.01 million and generates $12.40 million in revenue each year. The company earns $-101,070,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Stoke Therapeutics have?

The company employs 102 workers across the globe.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com.

This page (NASDAQ:STOK) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -